

02-27-2003

2-25-03



102375580

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

1. Name of conveying party(ies):

Novartis Corporation

2. Name and address of receiving party(ies)

Name: Novartis Finance Corporation

Internal Address: _____

Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

3. Nature of conveyance:

☒ Assignment☐ Merger☐ Security Agreement☐ Change of Name☐ Other _____Street Address: 608 Fifth AvenueCity: New York State: NY ZIP: 10020Execution Date: January 23, 2003Additional name(s) & address(es) attached? ☐ Yes ☒ No

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is: _____

A. Patent Application No.(s)

09/726,081

B. Patent No.(s)

5,231,019; 5,453,367; and 6,201,169

Additional numbers attached? ☐ Yes ☒ No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Larry W. StultsInternal Address: Syngenta Biotechnology, Inc.
Patent DepartmentStreet Address: 3054 Cornwallis RoadCity: Research Triangle Park State: NC ZIP: 277096. Total number of applications and patents involved: 47. Total fee (37 CFR 3.41) \$ 160.00☒ Please charge Applicant's Credit Card. A Credit Card Payment Form is enclosed.

8. Deposit account number:

50-1744 (in the name of Syngenta Biotechnology, Inc.)

(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature.

*To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.*Randee S. SchwartzName of Person Signing
Reg. No. 45,085

Signature

2/20/03
Date

Total number of pages including cover sheet, attachments, and document: 3

Mail documents to be recorded with required cover sheet information to:

Box: Assignment, Commissioner for Patents
Washington, D.C. 20231

PATENT

REEL: 013774 FRAME: 0370

ASSIGNMENT

Whereas, Novartis Corporation, 608 Fifth Avenue, New York, NY 10020, a corporation of New York, is the assignee and legal owner of the entire right, title and interest in each of United States Patents 5,231,019, 5,453,367 and 6,201,169, abandoned United States Patent Application Nos. 06/730,025, 07/157,115 and 07/366,285 and pending United States Patent Application No. 09/726,081;

Whereas, Novartis Corporation was formerly known as Ciba-Geigy Corporation, the change of name having been recorded in the Patent and Trademark Office on October 13, 1998 (Reel 9507, Frames 0112-0114); and


Whereas, in accordance with a resolution of the Board of Directors of Ciba-Geigy Corporation (now Novartis Corporation) made on December 20, 1996, Novartis Corporation wishes to assign its entire interest in each of United States Patents 5,231,019, 5,453,367 and 6,201,169, abandoned United States Patent Application Nos. 06/730,025, 07/157,115 and 07/366,285 and pending United States Patent Application No. 09/726,081 to Novartis Finance Corporation, 608 Fifth Avenue, New York, NY 10020, a corporation of New York, and said Novartis Finance Corporation wishes to acquire Novartis Corporation's interest in said patents and abandoned and pending patent applications.

Now, therefore, Novartis Corporation hereby assigns to Novartis Finance Corporation and its successors and assigns its entire right, title and interest in (1) (a) each of United States Patents 5,231,019, 5,453,367 and 6,201,169, (b) any and all applications for reissues of said patents, (c) any and all reissues of said patents that may be issued and/or granted, (d) any and all applications for extensions of said patents (including reissue patents) and for reexamination certificates for said patents (including reissue patents) and (e) any and all extensions of said patents (including reissue patents) that may be issued and/or granted and reexamination certificates that may be issued for said patents (including reissue patents), (2) abandoned United States Patent Application Nos. 06/730,025, 07/157,115 and 07/366,285 and (3) (a) United States Patent Application No. 09/726,081, (b) any and all continuations and divisions of said application (including further continuations and divisions such as, but not limited to, continuations and divisions of continuations), (c) any and all patents that may be issued and/or granted on all of said applications, (d) any and all applications for reissues of said patents, (e) any and all reissues of said patents that may be issued and/or granted, (f) any and all applications for extensions of said patents (including reissue patents) and for reexamination certificates for said patents (including reissue patents) and (g) any and all extensions of said patents (including reissue patents) that may be issued and/or granted and reexamination certificates that may be issued for said patents (including reissue patents), including, in the case of all patents (including reissue patents within the scopes of (1) and (3), the right to sue, and to obtain damages, for past infringement, said right, title and interest conveyed herein by Novartis Corporation to Novartis Finance Corporation constituting the entire right, title and interest in said patents (including reissue patents), abandoned applications, pending application, extensions and reexamination certificates.

In witness whereof, Novartis Corporation has caused this Assignment to be signed by its duly authorized corporate officer.

Signed this 23rd day of January 2003.

Novartis Corporation

A handwritten signature in dark ink, appearing to read 'THOMAS HOXIE', is written over a horizontal line.

Thomas Hoxie
Vice-President